M A H Sonneveld1, M Kavousi2, M A Ikram2,3,4, A Hofman2,5, O L Rueda Ochoa2,6, P L Turecek7, O H Franco2, F W G Leebeek1, M P M de Maat1. 1. Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands. 2. Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands. 3. Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands. 4. Department of Radiology, Erasmus University Medical Center, Rotterdam, the Netherlands. 5. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 6. School of Medicine, Faculty of Health, Universidad Industrial de Santander, Bucaramanga, Colombia. 7. Baxalta Innovations, Vienna, Austria.
Abstract
Essentials An association between ADAMTS-13 and coronary heart disease (CHD) has been suggested. 5688 participants ≥ 55 years from the Rotterdam Study without a history of CHD were included. Over a median follow-up time of 9.7 years, 456 individuals suffered from CHD. Low ADAMTS-13 activity was associated with an increased CHD risk. SUMMARY: Background The metalloprotease ADAMTS-13 cleaves high-molecular-weight von Willebrand factor multimers into smaller, less procoagulant forms. Low ADAMTS-13 activity is associated with an increased risk of ischemic stroke but its pathogenic role in coronary heart disease (CHD) is unclear. Objectives We aimed to determine the association between ADAMTS-13 activity and the risk of CHD in a large prospective population-based cohort study. Methods A total of 5688 participants of the Rotterdam Study, a population-based cohort study involving individuals aged ≥ 55 years without a history of CHD, were included. ADAMTS-13 activity was measured by the FRETS-VWF73 assay and VWF:Ag levels by ELISA. We assessed the association between ADAMTS-13 activity, VWF:Ag levels and CHD using Cox proportional hazard regression analysis, adjusting for cardiovascular risk factors. Results Over a median follow-up time of 9.7 years, 456 individuals suffered from CHD. A low ADAMTS-13 activity (quartile 1) was associated with an increased CHD risk (HR 1.42, 95% CI 1.07-1.89) compared with the reference highest quartile. Conclusions Low ADAMTS-13 activity is associated with an increased risk of CHD in the elderly, independently of VWF and established cardiovascular risk factors.
Essentials An association between ADAMTS-13 and coronary heart disease (CHD) has been suggested. 5688 participants ≥ 55 years from the Rotterdam Study without a history of CHD were included. Over a median follow-up time of 9.7 years, 456 individuals suffered from CHD. Low ADAMTS-13 activity was associated with an increased CHD risk. SUMMARY: Background The metalloprotease ADAMTS-13 cleaves high-molecular-weight von Willebrand factor multimers into smaller, less procoagulant forms. Low ADAMTS-13 activity is associated with an increased risk of ischemic stroke but its pathogenic role in coronary heart disease (CHD) is unclear. Objectives We aimed to determine the association between ADAMTS-13 activity and the risk of CHD in a large prospective population-based cohort study. Methods A total of 5688 participants of the Rotterdam Study, a population-based cohort study involving individuals aged ≥ 55 years without a history of CHD, were included. ADAMTS-13 activity was measured by the FRETS-VWF73 assay and VWF:Ag levels by ELISA. We assessed the association between ADAMTS-13 activity, VWF:Ag levels and CHD using Cox proportional hazard regression analysis, adjusting for cardiovascular risk factors. Results Over a median follow-up time of 9.7 years, 456 individuals suffered from CHD. A low ADAMTS-13 activity (quartile 1) was associated with an increased CHD risk (HR 1.42, 95% CI 1.07-1.89) compared with the reference highest quartile. Conclusions Low ADAMTS-13 activity is associated with an increased risk of CHD in the elderly, independently of VWF and established cardiovascular risk factors.
Authors: M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman Journal: Eur J Epidemiol Date: 2017-10-24 Impact factor: 8.082
Authors: Harshvardhan Upreti; Jamil Kasmani; Kathryn Dane; Evan M Braunstein; Michael B Streiff; Satish Shanbhag; Alison R Moliterno; C John Sperati; Rebecca F Gottesman; Robert A Brodsky; Thomas S Kickler; Shruti Chaturvedi Journal: Blood Date: 2019-08-20 Impact factor: 22.113
Authors: Max A Brodsky; Senthil Sukumar; Sruthi Selvakumar; Lisa Yanek; Sarah Hussain; Marshall A Mazepa; Evan M Braunstein; Alison R Moliterno; Thomas S Kickler; Robert A Brodsky; Spero R Cataland; Shruti Chaturvedi Journal: Am J Hematol Date: 2021-09-15 Impact factor: 10.047
Authors: Nina Buchtele; Michael Schwameis; James C Gilbert; Christian Schörgenhofer; Bernd Jilma Journal: Thromb Haemost Date: 2018-05-30 Impact factor: 5.249
Authors: Darae Ko; Mark D Benson; Debby Ngo; Qiong Yang; Martin G Larson; Thomas J Wang; Ludovic Trinquart; David D McManus; Steven A Lubitz; Patrick T Ellinor; Ramachandran S Vasan; Robert E Gerszten; Emelia J Benjamin; Honghuang Lin Journal: J Am Heart Assoc Date: 2019-03-19 Impact factor: 5.501
Authors: M Arfan Ikram; Guy Brusselle; Mohsen Ghanbari; André Goedegebure; M Kamran Ikram; Maryam Kavousi; Brenda C T Kieboom; Caroline C W Klaver; Robert J de Knegt; Annemarie I Luik; Tamar E C Nijsten; Robin P Peeters; Frank J A van Rooij; Bruno H Stricker; André G Uitterlinden; Meike W Vernooij; Trudy Voortman Journal: Eur J Epidemiol Date: 2020-05-04 Impact factor: 8.082
Authors: Frank J Wolters; Johan Boender; Paul S de Vries; Michelle A Sonneveld; Peter J Koudstaal; Moniek P de Maat; Oscar H Franco; M Kamran Ikram; Frank W Leebeek; M Arfan Ikram Journal: Sci Rep Date: 2018-04-03 Impact factor: 4.379